We've found
10,036 Brain Cancer
clinical trials
We've found
10,036 Brain Cancer
clinical trials
Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Low-grade Glioma Clinical Trial
Updated: 12/31/1969
TAK-580 In Gliomas and Other Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 2/28/2018
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Status: Enrolling,
Phase
I, II
Updated: 2/28/2018
Click here to add this to my saved trials

Endocrinology, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Glioblastoma Clinical Trial
Updated: 12/31/1969
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Phase I Study of APX005M in Pediatric CNS Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Recurrent and Refractory Solid Tumors Clinical Trial
Updated: 12/31/1969
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Recurrent and Refractory Solid Tumors Clinical Trial
Updated: 12/31/1969
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Recurrent and Refractory Solid Tumors Clinical Trial
Updated: 12/31/1969
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Recurrent and Refractory Solid Tumors Clinical Trial
Updated: 12/31/1969
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Recurrent and Refractory Solid Tumors Clinical Trial
Updated: 12/31/1969
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Neurology, Oncology, Reproductive Clinical Trial
Updated: 3/19/2018
A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)
Status: Enrolling
Updated: 3/19/2018
Click here to add this to my saved trials

Oncology, Psychiatry / Psychology Clinical Trial
Updated: 12/31/1969
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Glioblastoma Clinical Trial
Updated: 3/20/2018
Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy
Status: Enrolling
Updated: 3/20/2018
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of XmAb®18087 in Subjects With NET and GIST
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of XmAb®18087 in Subjects With NET and GIST
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of XmAb®18087 in Subjects With NET and GIST
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
A Study of XmAb®18087 in Subjects With NET and GIST
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
ONC201 in Pediatric H3 K27M Gliomas
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
